TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24434526
Drug: Rivastigmine capsules
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine capsules (12 mg/d)
Study: 19122080
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of normal saline solution at a rate of 5 mL/sec through an 18-gauge needle at the inferomedial location
Study: 19122080
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of normal saline solution at a rate of 5 mL/sec through an 18-gauge needle at the superomedial location
Study: 19122080
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of normal saline solution to diagnose 50% of arthrotomies
Study: 19122080
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of normal saline solution to diagnose 75% of arthrotomies
Study: 19122080
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of normal saline solution to diagnose 90% of arthrotomies
Study: 19122080
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of normal saline solution to diagnose 95% of arthrotomies
Study: 19122080
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of normal saline solution to diagnose 99% of arthrotomies
Study: 17222324
Drug: Hydroxyzine 25
Normalized name: hydroxyzine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 25 mg at bedtime
Study: 15605774
Drug: Karinat (antioxidant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Karinat (antioxidant dietary supplement)
Study: 9786536
Drug: Sublingual hyoscyamine
Normalized name: hyoscyamine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual hyoscyamine sulfate (0.125 mg)
Study: 9786536
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac tromethamine (30 mg)
Study: 7602722
Drug: Diet supplemented
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet supplemented with 20 g of soluble fiber (partially hydrolyzed guar gum, Sunfiber)
Study: 27819483
Drug: Music listening
Normalized name: Listerine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music listening (ML) (n = 54)
Study: 18338278
Drug: TENS therapy
Normalized name: Walgreens Electronic TENS Therapy Pain Relief Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS therapy (20 minutes, 15 sessions over 3 weeks)
Study: 9683949
Drug: Intravenous teicoplanin
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous teicoplanin (5 patients each at 1 h, 12 h, 24 h pre-operatively, and 24 h and 48 h pre-operatively)
Study: 9683949
Drug: Topical teicoplanin
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical teicoplanin drops (5 patients, half-hourly for 6 h before vitrectomy)
Study: 24702251
Drug: Hydralazine (83
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (83 mg for slow acetylators, 182 mg for fast acetylators)
Study: 24702251
Drug: Valproate (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate (700 mg every 8 hours)
Study: 17008798
Drug: Active EECP
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active EECP therapy
Study: 16120091
Drug: HMR 1031
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMR 1031 (20 mg b.i.d.)
Study: 9451475
Drug: Pravastatin, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin, 20 mg/day
Study: 3131256
Drug: Fat infusion
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat infusion (1.2 g fat/kg B.W./day)
Study: 26749228
Drug: Gabapentin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1200 mg, 600 mg 8 hours before and 600 mg 2 hours before anesthesia induction)
Study: 24255597
Drug: Micronutrient supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient supplement (Perfectil® Platinum)
Study: 21804509
Drug: Oral levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral levofloxacin 750mg once daily for 7 days
Study: 21804509
Drug: Injectable levofloxacin
Normalized name: levofloxacin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable levofloxacin 500mg once daily for 7 days
Study: 16452280
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care (medication and counseling for up to 12 months)
Study: 16452280
Drug: Receipt of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receipt of preferred treatment
Study: 15265539
Drug: Good oral
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Good oral hygiene
Study: 9002119
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin alone (Group I)
Study: 9002119
Drug: Ciprofloxacin plus
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin plus inhaled amikacin (Group II)
Study: 31399540
Drug: Combined perineural
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined perineural dexmedetomidine (1 µg/kg) and dexamethasone (10 mg) in 2 mL (RSM group)
Study: 31399540
Drug: Perineural dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perineural dexamethasone (10 mg) in 2 mL (RS group)
Study: 31399540
Drug: Perineural dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perineural dexmedetomidine (1 µg/kg) in 2 mL (RM group)
Study: 26466937
Drug: Risedronate (48-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (48-week treatment)
Study: 22572234
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus injection of 0.375% ropivacaine into intrapleural space (IPA group, n = 20)
Study: 17053894
Drug: Bread meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bread meal before itraconazole administration
Study: 17053894
Drug: Rice meal
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice meal before itraconazole administration
Study: 10376571
Drug: Raloxifene, 60
Normalized name: Raloxifene, 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene, 60 mg, 2 tablets daily
Study: 8629721
Drug: New treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatment (specific details not provided)
Study: 8629721
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (specific details not provided)
Study: 1381330
Drug: Combaren (diclofenac-Na
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combaren (diclofenac-Na 50 mg + codeine phosphate 50 mg)
Study: 1381330
Drug: diclofenac-Na 50
Normalized name: diclofenac sodium 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac-Na 50 mg (Voltaren 50)
Study: 6421009
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ISDN (acute administration)
Study: 6421009
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ISDN (chronic treatment, four doses daily)
Study: 6421009
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ISDN (acute administration)
Study: 6421009
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ISDN (long-term treatment, twice daily)
Study: 6421009
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg NTG (sublingual during treatment with 40 mg ISDN)
Study: 30248052
Drug: Antipsychotics, citalopram,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotics, citalopram, or placebo (duration: up to 36 weeks, mean 252±52 days)
Study: 25023458
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with therapeutic apheresis and haemopheresis with Albutein® and intravenous immunoglobulin (Flebogamma® DIF)
Study: 23405791
Drug: Compound Xuanju
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Xuanju Capsule (CXC) at 3 g tid plus sildenafil at 50 mg an hour before sexual activity
Study: 23405791
Drug: Sildenafil alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil alone at 100 mg an hour before sexual activity
Study: 19093205
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of Taiproton (generic lansoprazole)
Study: 19093205
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of Tapizol (generic lansoprazole)
Study: 19093205
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of Lansoral (generic lansoprazole)
Study: 9594519
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural injection of buprenorphine (0.2 mg) with 0.25% bupivacaine (40 ml) for 24 hours (Group A)
Study: 9594519
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of buprenorphine (0.2 mg) followed by continuous injection of buprenorphine (0.2 mg) with 0.25% bupivacaine (40 ml) for 24 hours (Group B)
Study: 9594519
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of buprenorphine (0.2 mg) followed by continuous buprenorphine infusion with normal saline (Group C)
Study: 9594519
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural injection of buprenorphine (Group C)
Study: 8207739
Drug: Ro 42-5892
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 42-5892 (100 mg once daily orally)
Study: 8207739
Drug: Ro 42-5892
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 42-5892 (10 mg intravenously)
Study: 2530925
Drug: 75 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 micrograms fentanyl with 12 ml of 0.25% plain bupivacaine
Study: 2530925
Drug: 15 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 micrograms sufentanil with 12 ml of 0.25% plain bupivacaine
Study: 2530925
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (saline with 12 ml of 0.25% plain bupivacaine)
Study: 28632487
Drug: Cytarabine plus
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine plus high-dose daunorubicin (AD)
Study: 28632487
Drug: Cytarabine plus
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine plus high-dose daunorubicin (AD) in patients with FLT3 ITD mutation
Study: 19796205
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with house dust mite extracts
Study: 16500336
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E with conjugated equine estrogen (CEE) (0.625 mg)
Study: 16500336
Drug: CEE (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE (0.625 mg) plus medroxyprogesterone acetate (MPA) (2.5 mg)
Study: 10955327
Drug: naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 500 mg bid (n = 1,099)
Study: 10955327
Drug: celecoxib 50
Normalized name: celecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: celecoxib 50 mg bid (n = 690)
Study: 10955327
Drug: celecoxib 100
Normalized name: celecoxib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: celecoxib 100 mg bid (n = 1,131)
Study: 10955327
Drug: celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: celecoxib 200 mg bid (n = 1,125)
Study: 10955327
Drug: celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: celecoxib 400 mg bid (n = 434)
Study: 8968014
Drug: Low-dose chlorthalidone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose chlorthalidone (12.5-25.0 mg/d) with step-up to atenolol (25.0-50.0 mg/d) or reserpine (0.05-0.10 mg/d)
Study: 1316075
Drug: Lomefloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin (400 mg once daily)
Study: 29901417
Drug: Exercise +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise + supplement (ES) group
Study: 29901417
Drug: Supplement (S)
Normalized name: S-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement (S) group
Study: 26335787
Drug: Standard antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotics plus pidotimod (PDT)
Study: 26335787
Drug: Standard antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotics alone
Study: 18496296
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg daily (n=27)
Study: 18496296
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg daily (n=28)
Study: 16796157
Drug: Reduced-osmolarity ORS
Normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-osmolarity ORS solution (245 mmol/L)
Study: 16796157
Drug: Standard WHO-ORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard WHO-ORS solution (311 mmol/L)
Study: 12657118
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b plus radiation therapy
Study: 11048902
Drug: Olanzapine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5 to 25 mg orally once daily for 18 weeks)
Study: 9072308
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg dolasetron
Study: 9072308
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg dolasetron
Study: 9070501
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of dolasetron
Study: 29859385
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (50,000 IU every 2 weeks) plus omega-3 fatty acid (2000 mg/day)
Study: 24420547
Drug: 100,000 U
Normalized name: nystatin 100,000 UNT Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100,000 U oral vitamin D3 every 2 months
Study: 8266016
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg sulglycotide three times daily (n = 50)
Study: 27086046
Drug: Mental Incisal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mental Incisal Nerve Block (MINB) with 2 mL 2% lidocaine with 1:200,000 epinephrine and a mock IANB with 2 mL sterile saline
Study: 27086046
Drug: Inferior Alveolar
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inferior Alveolar Nerve Block (IANB) with 2 mL 2% lidocaine
Study: 27086046
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MINB and IANB with 2 mL each of 2% lidocaine
Study: 25065535
Drug: Brief motivational
Normalized name: ALCOHOL 300 mL in 375 mL TOPICAL LIQUID [Nelsons Clean Brier Tennessee Handwash]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief motivational interviewing and cognitive behavioural therapy (MI-CBT) intervention (up to 12 sessions over 4.5 months) with standard care
Study: 25065535
Drug: Long motivational
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long motivational interviewing and cognitive behavioural therapy (MI-CBT) intervention (up to 24 sessions over 9 months) with standard care
Study: 20163375
Drug: Renzapride 4
Normalized name: Renzapride
DrugBank: Renzapride (DB04917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renzapride 4 mg daily
Study: 17453011
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy (OT) program combined with neuromotor rehabilitation
Study: 12186803
Drug: Abnormal renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abnormal renal function (creatinine clearance <70 mL/min) in the STE group
Study: 12186803
Drug: Abnormal renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abnormal renal function (creatinine clearance <70 mL/min) in the NSE group
Study: 7992239
Drug: Diet rich
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet rich in fish (250 g daily for six weeks)
Study: 2538300
Drug: Isocaloric diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric diet rich in fibres (70 g/day)
Study: 2538300
Drug: Isocaloric diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric diet enriched by guar (9 g of guar added to 30 g of natural fibres/day)
Study: 29122523
Drug: 0.2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g/kg of a 20% SCIg solution (IgPro20) weekly
Study: 29122523
Drug: 0.4 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg of a 20% SCIg solution (IgPro20) weekly
Study: 29122523
Drug: Placebo (2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2% human albumin solution)
Study: 29122523
Drug: 0.2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g/kg SCIg vs Placebo
Study: 29122523
Drug: 0.4 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg SCIg vs Placebo
Study: 29122523
Drug: 0.4 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg SCIg vs 0.2 g/kg SCIg
Study: 27633186
Drug: Semaglutide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide (0.5 mg or 1.0 mg)
Study: 23153360
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard school uniforms without insecticide treatment)
Study: 21142442
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy including lopinavir/ritonavir
Study: 17484706
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GG (LGG) in the form of commercially available yoghurt, 100 g daily for 4 weeks
Study: 14764410
Drug: Selegiline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (10 mg per os daily for 120 days)
Study: 2344897
Drug: Quinidine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (1200 mg/die)
Study: 2344897
Drug: Lidoflazine (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidoflazine (240 mg/die)
Study: 29231159
Drug: Intra-articular lumbar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular lumbar facet-joint injections with steroids
Study: 15125520
Drug: Daily topical
Normalized name: Clindagel 1 % Once-Daily Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily topical application of 1/3 diluted camphor oil with glycerol and 500 mg metronidazole orally for fifteen days
Study: 11779901
Drug: Acetaminophen 650
Normalized name: acetaminophen 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650 mg every 4 hours for 24 hours
Study: 9640568
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (group A)
Study: 8074628
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 4 mg.kg‐1
Study: 2561141
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nifedipine twice a day
Study: 2561141
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg enalapril once a day
Study: 25970252
Drug: D-cycloserine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine (50 mg) administered 1 hour before each of 5 exposure and response prevention tasks
Study: 25970252
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 1 hour before each of 5 exposure and response prevention tasks
Study: 19125674
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of Helicobacter pylori infection
Study: 28453838
Drug: Multivalent GI.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivalent GI.1 and GII.4c norovirus VLP vaccine candidate adjuvanted with alum and MPL
Study: 26515660
Drug: Combined donepezil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined donepezil discontinuation groups
Study: 18663402
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of ibandronate (ACE doses > or = 10.8 mg: 150 mg once monthly, 3 mg i.v. quarterly, 2 mg i.v. every 2 months)
Study: 18663402
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of ibandronate (ACE doses of 5.5 mg)
Study: 18663402
Drug: ACE doses
Normalized name: Zodryl AC
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE doses of 7.2‐12 mg
Study: 10679645
Drug: Lanreotide 30
Normalized name: lanreotide 300 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide 30 mg intramuscularly every 10 days for 1 month